Financial Data and Key Metrics Changes - The company reported revenue of approximately $2.5 billion, an increase of 1.9% on a constant currency basis and over 5% on a reported basis [8] - Non-GAAP operating income was $295 million, and adjusted EBITDA was $348 million, with a margin of 13.9% [9] - Non-GAAP diluted EPS was $2.61, in line with guidance [9] - Adjusted free cash flow was negative $145 million, reflecting an increase in accounts receivable [10] Business Line Data and Key Metrics Changes - Revenue from banking and financial services clients grew 13% year-over-year, while retail, travel, and e-commerce clients grew 6% [8] - Media and communications revenues grew 3%, primarily from clients outside the U.S. [8] - Technology and consumer electronics verticals decreased about 6%, driven by lighter volumes than expected [8] Market Data and Key Metrics Changes - The company noted a solid demand environment, with a significant increase in AI-related bookings, which more than doubled [5] - The pipeline of opportunities remains strong, indicating a shift towards a higher solution mix [5] Company Strategy and Development Direction - The company is focused on securing complex work and high-value services, leveraging proprietary AI technologies to differentiate in the market [6] - There is an emphasis on driving internal efficiencies to fuel continued investment in areas of new growth [6] - The company aims to reduce net leverage to below 2.6 times adjusted EBITDA by the end of fiscal 2026 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive year-over-year profitability growth in the second half of 2026 [16] - The geopolitical situation has had minimal impact on client behavior, with exposure to such risks being about 1% of revenue [51] - Management expects margin improvement in the second half of the year due to cost actions and increased revenue [25][27] Other Important Information - The company returned approximately $65 million to shareholders, including share repurchases and dividends [11] - The company issued $600 million of 3-year senior notes to refinance existing debt [12] Q&A Session Summary Question: Revenue related to AI and iX suite - Management indicated that the iX Hello solution is priced by consumption, leading to initial negative margins that turn positive as scale increases [19] - The iX Hero product operates on a subscription basis, with expectations to reach or exceed $100 million in annual recurring revenue by the end of the fiscal year [20] Question: Margin improvement cadence - Management expects margins to be somewhat compressed in the first half, with sequential expansion in the second half driven by cost actions and additional revenue [25][27] Question: Impact of offshore movement on revenues - Approximately 15% of revenue is delivered from North America and Western Europe, with a projected 2-point headwind from onshore movement [29] Question: Philosophy behind divestitures - The divestitures of two small non-strategic businesses were made as they were not growing or accretive to overall margins, with no imminent plans for further divestitures [35] Question: Stability of banking and retail growth - Management expects sustained growth in banking and retail, driven by complex work and new solutions being offered [44][46]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled $36.4 million [22] - Total operating expenses for Q4 2025 were $14.7 million, and for the full year, they were $54.9 million, reflecting ongoing investments in regulatory, clinical, and commercial activities [22] - The total net loss for Q4 2025 was $14.7 million, and for the full year, it was $54.7 million [22] Business Line Data and Key Metrics Changes - The NDA submission in June 2025 marked a transition for the company from clinical development to a commercially focused enterprise [4] - The company aims to make cytisinicline available to 25 million smokers and nearly 18 million vapers in the U.S. [4] - The ORCA-OL long-term exposure trial demonstrated cytisinicline's safety profile, showing strong tolerability and excellent patient satisfaction [6] Market Data and Key Metrics Changes - Approximately 25 million adults in the U.S. smoked cigarettes in 2024, with over 15 million attempting to quit annually [10] - There are 6 million COPD smokers in the U.S. with limited options to help them quit, highlighting the need for effective treatments [6] Company Strategy and Development Direction - The company is focused on launching cytisinicline as the first FDA-approved treatment for nicotine dependence in 20 years [5] - Achieve Life Sciences is building a scalable, data-driven commercial model to effectively target physicians and patients [7] - The partnership with Adare Pharma Solutions aims to secure the supply chain and reduce risks associated with international pharmaceutical importation [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory progress and the potential for cytisinicline to deliver a new treatment option for nicotine dependence [16] - The company is committed to addressing the public health crisis of nicotine dependence and is actively building for the product launch [24] - The management emphasized the importance of a controlled and successful launch, ensuring all processes are in place [32] Other Important Information - The company received the FDA Commissioner's National Priority Voucher for vaping cessation, which provides an expedited review timeline [16] - The Willpower awareness campaign was launched to reframe the conversation around nicotine dependence as a medical condition [11] Q&A Session Summary Question: Can you talk about the critical path between a late June NDA approval and a first half launch? - The company needs to ensure drug availability in the supply chain before market entry, with all trade and distribution processes ready upon drug availability [27][28] Question: Did you imply that the manufacturer in the NDA will not be supplying commercial product, rather Adare will? - The company confirmed that the PDUFA date remains unchanged, and the decision to transfer manufacturing to the U.S. was made to ensure supply chain security [33] Question: Can you talk about healthcare provider awareness and additional work in 2026? - The company has been conservative in spreading awareness prior to product availability but plans to ramp up educational efforts as the launch approaches [38] Question: What is the status of the FDA dialogue on the vaping indication since receiving the CMPV? - Discussions with the FDA have focused on protocol approval, with site selection for the ORCA-V2 phase III trial already underway [40][41] Question: How robust is the raw plant material supply chain? - The company has been stockpiling starting material and expects to have more than three years' supply by the time of launch [56] Question: What is the cytisinicline dosing schedule and potential compliance concerns? - High adherence rates were reported in trials, with participants finding the dosing schedule manageable and effective in addressing cravings [58][59] Question: What are the pricing considerations for cytisinicline? - The company is not ready to comment on pricing but acknowledges the substantial unmet need highlighted in the ICER report [62][65]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年年度報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年3 月2 4 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * 僅供識別 上海复星 ...

Group 1 - The article emphasizes the importance of young business leaders under 40 years old as key players in shaping the future of commerce in China [2][3] - It highlights that these leaders are driving innovation through new business models and technological advancements, such as artificial intelligence and hard tech entrepreneurship, which are redefining industry standards [3] - The article announces the 16th edition of the "Fortune" list of 40 under 40 Chinese business elites, aiming to recognize those who drive growth through innovation and social responsibility [3] Group 2 - The selection process involves independent research and evaluation by the editorial team after candidates submit their applications [4] - Candidates must be founders or co-founders of companies with strong social responsibility and innovative products, and must be under 40 years old at the time of the list's publication [8] - The application requires basic information about the candidate and their company, including business model, company size, and industry position, along with a focus on technological innovation, business model innovation, or social impact [8]

Core Viewpoint - The overall market sentiment entering 2026 remains stable, despite previous policy fluctuations and geopolitical tensions, with major indices like the S&P 500, Dow Jones, and Nasdaq showing significant returns in the past year [1] Group 1: Market Conditions and Sentiment - Analysts recognize that the conditions supporting market prosperity are becoming increasingly stringent, with optimism primarily driven by expectations surrounding artificial intelligence (AI) [3][4] - The term "precarious" has been used to summarize the outlook for 2026, indicating a coexistence of strong long-term trends and structural vulnerabilities [4] Group 2: AI Investment and Risks - The balance between opportunities and excess enthusiasm in the AI sector is seen as the most challenging aspect for investors in 2026, with significant capital expenditure in the tech sector projected to exceed $500 billion by 2026 [5] - Morgan Stanley has identified five indicators to measure irrational exuberance in the market, including capacity adequacy, credit availability, risk concealment, market heat, and valuation versus cash flow discrepancies [5][6] Group 3: Economic Outlook and Labor Market - Deutsche Bank's global outlook report suggests that 2026 will not be a quiet year, with potential trade tensions between the U.S. and China resurfacing [6][7] - The labor market's fragility is highlighted as a key weakness in the U.S. economy, with rising unemployment risks if layoffs increase [7][8] Group 4: Consumer Behavior and Economic Disparities - A K-shaped economic trend is emerging, where affluent consumers thrive while a significant portion of the population struggles financially [9] - Despite challenges, the overall economic outlook remains optimistic, with resilience noted in the face of tariffs and labor supply issues [9][10] Group 5: Macro Trends and Investment Strategies - The concept of "fragile growth" is emphasized, indicating that U.S. financial market growth in 2026 will depend on a few stringent conditions, suggesting a need for cautious global asset allocation strategies [10]

Financial Data and Key Metrics Changes - For the full year 2025, revenue was $365.3 million, representing a 4.7% year-over-year growth, primarily driven by double-digit international expansion, particularly in APAC, which grew by 26.9% [5][14] - Gross profit for 2025 was $215.1 million, with a gross margin of 58.9%, down from 62.1% in 2024, attributed to shifts in geographic and product mix and new import tariffs [17] - Adjusted net profit for 2025 was $31 million, up 7.9% year-on-year, with an adjusted net profit margin of 8.5%, reflecting disciplined cost management and efficiency gains [17] Business Line Data and Key Metrics Changes - Energy-based devices (EBD) revenue was $310.4 million, representing 85% of total revenue, essentially flat year-on-year, supported by strong demand for Alma Harmony and Alma Hybrid platforms [14][15] - Injectable revenues reached $28 million, up 185.6% year-on-year, reflecting significant diversification due to Profhilo's momentum and broader adoption by practitioners [15] Market Data and Key Metrics Changes - North America revenue was $111 million, down 19.2% year-on-year, impacted by weakened macroeconomic conditions and softer consumer demand [14] - International markets, excluding North America, grew 20.1%, led by Asia-Pacific, which rose 26.9% year-on-year, serving as the primary growth engine [14] Company Strategy and Development Direction - The company is focused on building a broader ecosystem that integrates technologies, diagnostics, injectables, and digital capabilities to adapt to evolving market demands [3][4] - Plans for 2026 include strengthening the flagship device portfolio, expanding the global energy-based device offering, and introducing additional EBD solutions in Thailand [7][10] - The company aims to capture long-term growth opportunities in the global medical aesthetics market while maintaining operational discipline in North America [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the new executive team and their ability to lead the company with a focus on execution, operational discipline, and long-term value creation [4] - The company anticipates a recovery in the U.S. market in 2026, contingent on improvements in macroeconomic conditions and interest rates [49] Other Important Information - The company completed a structured leadership transition and is committed to balancing reinvestment for sustainable growth with shareholder value retention [4][17] - R&D spending was $16.9 million in 2025, reflecting ongoing investments in clinical programs and next-generation products [16] Q&A Session Summary Question: What specific measures are being taken to cut down the sales and marketing expense ratio? - Management indicated that proactive measures were taken to drive efficiency, resulting in reductions in sales and marketing expenses while still investing in strategic projects like DAXXIFY [20][21] Question: Can you provide an update on the company's R&D pipeline and expected clinical progress? - The company plans several launches in 2026, particularly in the hair growth segment, and is also assessing additional products for future opportunities [24][25] Question: What is the sales strategy for energy-based devices in China for 2026? - The company aims to maintain its dominant position in China and leverage synergies across different business segments to drive growth [28][29] Question: What are the plans for the commercialization of DAXXIFY this year? - The company has a capacity of 100,000 units for DAXXIFY and plans to target high-value clinics initially, with positive feedback received so far [34][35] Question: What is the strategic roadmap for 2026 and key growth drivers? - The strategy focuses on creating an ecosystem to provide more value to practitioners and enhance brand strength, with a strong emphasis on energy-based devices and hair growth solutions [38][40] Question: What are the underlying reasons for the softness in the U.S. segment and the potential for recovery? - Management noted that the decline was primarily due to macroeconomic conditions, but they are optimistic about recovery in 2026 with improved economic indicators [46][49] Question: What is the progress on AI-enabled products and the impact of geopolitical issues? - The company is leveraging partnerships for AI technologies and has maintained operational capacity despite geopolitical challenges, although there are impacts on shipping costs [56][58]

机器之心编辑部 这就是「中关村・北纬龙虾大赛决赛」现场，在 OpenClaw 大杀四方、引爆全球 AI 爱好者的当下，各路参赛选手大展身手，思考当「龙虾」技术与创意、灵感碰 撞后，是如何解决生产力、学术、生活等领域具体问题的。 乍一看，这不过是一场热闹的社区活动，但如果把它放进最近几个月海淀的整体氛围中，就会发现，它更像一个信号： AI，正在走出实验室，走向更广阔的「生 活化」场景。 过去，AI 更多是存在于论文、代码、算力和模型参数等抽象、晦涩的专业描述中，是少数人掌握叙事方式的高门槛能力。可如今，尤其是这一波以 OpenClaw 为 代表的技术狂欢，似乎让 AI 第一次真正具备了普及性，模型能力显著提升、技术门槛大幅降低、各类应用快速迭代…… 在这样的背景下，一种新的群体开始出现 —— OPC（One Person Company，一人公司）， 越来越多的「超级个体」开始用 AI 完成过去需要团队协作才能完成的 工作，AI 正从技术能力变成可被个体调度的生产力工具。 而此次龙虾大赛这样的场景，正是这种变化的具象体现…… 其实不仅是「龙虾大赛」，诸如此类的活动在海淀常常举办，比如将于 3 月 25 日至 2 ...

Investment Rating - The report rates the electronic industry as "Outperform" compared to the market [1]. Core Insights - NVIDIA's GTC 2026 introduced the Vera Rubin full-stack AI computing platform and the next-generation Feynman architecture, indicating a significant technological evolution in AI computing [2][5]. - The Vera Rubin platform features a new Vera CPU and Groq 3 LPU, creating a collaborative computing system that enhances AI inference performance and reduces latency [15][21]. - The report highlights potential growth opportunities in SRAM, new liquid cooling technologies, and CPO optical chips as a result of NVIDIA's advancements [37]. Summary by Sections NVIDIA's Technological Advancements - NVIDIA has transitioned from Tesla and Fermi architectures to the Vera Rubin and Feynman architectures, marking a significant leap in GPU technology from graphics acceleration to general-purpose parallel computing [6][8]. - The Vera Rubin platform integrates a new Vera CPU optimized for AI inference and a Groq 3 LPU designed for low-latency processing, significantly improving performance metrics [19][21]. Liquid Cooling Technology - The Vera Rubin platform employs a 100% liquid cooling architecture, which enhances cooling efficiency and reduces operational costs compared to traditional air and liquid cooling methods [26][27]. - This new cooling technology is expected to gradually replace conventional cooling solutions in data centers, improving overall energy efficiency [26]. CPO Optical Technology - NVIDIA launched the Spectrum-X Ethernet switch, the first CPO (Co-Packaged Optics) technology, which integrates optical modules directly into chip packaging, enhancing data center network bandwidth and efficiency [28]. - The CPO technology is anticipated to drive demand for copper and optical components in the industry [28]. Potential Beneficiaries - The report identifies several companies that may benefit from these technological advancements, including: - Beijing Junzheng, which focuses on SRAM and has a leading market share in automotive-grade SRAM [38]. - Gaolan Co., a specialist in thermal management solutions, which has seen revenue growth due to increased demand for liquid cooling systems [46]. - Chuanrun Co., which offers comprehensive liquid cooling solutions and has shown a recovery in revenue growth [50]. - Changguang Huaxin, which specializes in high-power semiconductor laser chips and has recently seen a rebound in performance [53]. - Yuanjie Technology, focusing on high-speed optical chips, has experienced significant revenue growth [61].

Tongcheng Travel Holdings Limited Stock Code: 0780 Investor Presentation March 2026 Disclaimer The materials used in this investors presentation are being furnished to you for your information only, which shall be kept in strict confidence. No representation or warranty, express or implied, is made by Tongcheng Travel Holdings Limited (the "Company") or its connected person, or any of their respective directors, officers, employees, advisers or representatives as to, and no reliance should be placed on, the ...

Xiaomi Corporation 2025 Fourth Quarter and Annual Results Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Xiaomi Corporation (the "Company", and together with its subsidiaries, the "Group") for use in presentations by the Group and does not constitute a recommendation regarding the securities of the Group. No part of t ...